Increasing pharmacoequity for people with cirrhosis.
作者信息
Hundt Melanie A, Kardashian Ani A
机构信息
Department of Medicine, Los Angeles General Hospital, Los Angeles, California, USA.
Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
出版信息
Clin Liver Dis (Hoboken). 2024 Jun 7;23(1):e0203. doi: 10.1097/CLD.0000000000000203. eCollection 2024 Jan-Jun.
Abstract
摘要
相似文献
1
Increasing pharmacoequity for people with cirrhosis.
Clin Liver Dis (Hoboken). 2024 Jun 7;23(1):e0203. doi: 10.1097/CLD.0000000000000203. eCollection 2024 Jan-Jun.
2
Pharmacoequity and Biologics in the Allergy Clinic: Providing the Right Care, at the Right Time, Every Time, to Everyone.
J Allergy Clin Immunol Pract. 2024 May;12(5):1170-1180. doi: 10.1016/j.jaip.2024.02.039. Epub 2024 Mar 6.
3
Pursuing Pharmacoequity: Determinants, Drivers, and Pathways to Progress.
J Health Polit Policy Law. 2022 Dec 1;47(6):709-729. doi: 10.1215/03616878-10041135.
4
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity.
Curr Atheroscler Rep. 2023 Dec;25(12):1113-1127. doi: 10.1007/s11883-023-01180-5. Epub 2023 Dec 18.
5
Pharmacoequity in Allergy-Immunology: Disparities in Access to Medications for Allergic Diseases and Proposed Solutions in the United States and Globally.
J Allergy Clin Immunol Pract. 2024 Feb;12(2):272-280. doi: 10.1016/j.jaip.2023.11.005. Epub 2023 Nov 10.
6
Reducing Health Disparities Through Achieving Pharmacoequity.
JAMA. 2022 Feb 8;327(6):589-590. doi: 10.1001/jama.2021.24519.
7
Reducing Health Disparities Through Achieving Pharmacoequity.
JAMA. 2022 Feb 8;327(6):588-589. doi: 10.1001/jama.2021.24516.
8
Reducing Health Disparities Through Achieving Pharmacoequity-Reply.
JAMA. 2022 Feb 8;327(6):590. doi: 10.1001/jama.2021.24538.
9
Pharmacoequity for Older Adults With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2024 Feb;22(2):209-214. doi: 10.1016/j.cgh.2023.11.012.
10
Examining Pharmacoequity in Older Inflammatory Bowel Disease Patients.
Gastroenterol Hepatol (N Y). 2024 Aug;20(8):435.
本文引用的文献
1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
2
Culture, stigma, and inequities creating barriers in alcohol use disorder management in alcohol-associated liver disease.
Clin Liver Dis (Hoboken). 2023 Mar 20;21(5):130-133. doi: 10.1097/CLD.0000000000000026. eCollection 2023 May.
3
Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.
Hepatol Commun. 2023 Mar 24;7(4). doi: 10.1097/HC9.0000000000000093. eCollection 2023 Apr 1.
4
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
JAMA Health Forum. 2021 Dec 17;2(12):e214182. doi: 10.1001/jamahealthforum.2021.4182. eCollection 2021 Dec.
5
Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1011-1017. doi: 10.15585/mmwr.mm7132e1.
6
Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy.
Clin Gastroenterol Hepatol. 2022 Aug;20(8S):S1-S8. doi: 10.1016/j.cgh.2022.04.036.
7
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States.
Hepatology. 2022 Dec;76(6):1649-1659. doi: 10.1002/hep.32527. Epub 2022 Apr 27.
8
Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
J Hepatol. 2022 Aug;77(2):377-382. doi: 10.1016/j.jhep.2022.02.010. Epub 2022 Mar 30.
9
Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.
J Viral Hepat. 2022 May;29(5):366-374. doi: 10.1111/jvh.13661. Epub 2022 Mar 19.
10
A Policy Prescription for Reducing Health Disparities-Achieving Pharmacoequity.
JAMA. 2021 Nov 9;326(18):1793-1794. doi: 10.1001/jama.2021.17764.
Zotero 插件